Most Intensive Ivermectin Use Had 74% Reduction In Excess Deaths In Peru: New Study

[Addict2sex]

Most Intensive Ivermectin Use Had 74% Reduction In Excess Deaths In Peru: New Study

COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State

Introduction In 2020, nations hastened to contain an emerging COVID-19 pandemic by deploying diverse public health approaches, but conclusive appraisals of the efficacy of these approaches are elusive in most cases. One of the medicines deployed, ivermectin (IVM), a macrocyclic lactone having...

www.cureus.com

COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State.

Juan J. Chamie • Jennifer A. Hibberd • David E. Scheim
Published: August 08, 2023
DOI: 10.7759/cureus.43168

Peer-Reviewed
Cite this article as: Chamie J J, Hibberd J A, Scheim D E (August 08, 2023) COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State. Cureus 15(8): e43168. doi:10.7759/cureus.43168


Abstract
Introduction
In 2020, nations hastened to contain an emerging COVID-19 pandemic by deploying diverse public health approaches, but conclusive appraisals of the efficacy of these approaches are elusive in most cases. One of the medicines deployed, ivermectin (IVM), a macrocyclic lactone having biochemical activity against SARS-CoV-2 through competitive binding to its spike protein, has yielded mixed results in randomized clinical trials (RCTs) for COVID-19 treatments. In Peru, an opportunity to track the efficacy of IVM with a close consideration of confounding factors was provided through data for excess deaths as correlated with IVM use in 2020, under semi-autonomous policies in its 25 states.

Methods
To evaluate possible IVM treatment effects, excess deaths as determined from Peruvian national health data were analyzed by state for ages ≥60 in Peru’s 25 states. These data were compared with monthly summary data for excess deaths in Peru for the period 2020-2021 as published by the WHO in 2022. To identify potential confounding factors, Google mobility data, population densities, SARS-CoV-2 genetic variations, and seropositivity rates were also examined.

Results
Reductions in excess deaths over a period of 30 days after peak deaths averaged 74% in the 10 states with the most intensive IVM use. As determined across all 25 states, these reductions in excess deaths correlated closely with the extent of IVM use (p<0.002). During four months of IVM use in 2020, before a new president of Peru restricted its use, there was a 14-fold reduction in nationwide excess deaths and then a 13-fold increase in the two months following the restriction of IVM use. Notably, these trends in nationwide excess deaths align with WHO summary data for the same period in Peru.

Conclusions
The natural experiment that was put into motion with the authorization of IVM use for COVID-19 in Peru in May 2020, as analyzed using data on excess deaths by locality and by state from Peruvian national health sources, resulted in strong evidence for the drug's effectiveness. Several potential confounding factors, including effects of a social isolation mandate imposed in May 2020, variations in the genetic makeup of the SARS-CoV-2 virus, and differences in seropositivity rates and population densities across the 25 states, were considered but did not appear to have significantly influenced these outcomes.

COVID-19 Excess Deaths in Peru’s 25 States in 2020: Nationwide Trends, Confounding Factors, and Correlations With the Extent of Ivermectin Treatment by State

Introduction In 2020, nations hastened to contain an emerging COVID-19 pandemic by deploying diverse public health approaches, but conclusive appraisals of the efficacy of these approaches are elusive in most cases. One of the medicines deployed, ivermectin (IVM), a macrocyclic lactone having...

www.cureus.com

PS. For all those believed in the mainstream media lies about not to use ivermectin because is for medications use for horse only not can be used as duel for people also , and had love one died or someone injured because of the lies or suffer from vaccine injury or long covid symptoms … . I suggested get a civil lawyer and a criminal lawyer. It time to hold the someone accountable.

 

[Addict2sex]

Most Intensive Ivermectin Use Had 74% Reduction In Excess Deaths In Peru: New Study

SATURDAY, AUG 19, 2023 - 02:30 PM
According to a new peer-reviewed ecological study, a natural experiment occurred when the government of Peru authorized ivermectin for use during the COVID-19 pandemic resulting in evidence of the drug’s effectiveness and ability to reduce excess deaths.

The paper’s results, published August 8 in Cureus, found a 74 percent reduction in excess deaths in 10 states with the most intensive ivermectin use over a 30-day period following peak deaths during the pandemic. When analyzing data across 25 states in Peru, researchers found these reductions in excess deaths correlated closely to ivermectin use during four months in 2020.
When ivermectin was available without restriction, there was a fourteenfold reduction in nationwide excess deaths. Once access to ivermectin was restricted by the government, a thirteenfold increase in excess deaths was observed in the two months following the limitation of its use. The findings align with summary data from the World Health Organization for the same time period in Peru.
Ivermectin is a widely-known and inexpensive treatment against parasitic diseases. Scientists believe the drug can also bind to the spike protein of the SARS-CoV-2 virus, limiting its morbidity and infectivity.
Peru Promoted Then Restricted Access to Ivermectin
Before Peru implemented COVID-19 vaccine mandates, the country relied on mitigation strategies such as lockdowns and therapeutics to control the SARS-CoV-2 virus that causes COVID-19, as did many other nations.
The Peruvian Ministry of Health, on May 8, 2020, approved ivermectin widely for use prompting 25 states in Peru to implement inpatient and outpatient treatments with ivermectin to different extents and in different time frames. Additionally, through the Mega-Operación Tayta (MOT)—a national program led by the Ministry of Defense—Peru’s government began distributing ivermectin on a wide scale.
Through a partnership with 11 other government agencies, MOT aimed to reach every targeted region with rapid response teams to detect COVID-19 cases, administer ivermectin, and provide food to encourage people to isolate for 15 days. Shortly thereafter, MOT began distributing the therapeutic to everyone identified as high-risk, regardless of whether they tested positive or were symptomatic for COVID-19.
The government of Peru independently tracked daily COVID-19 deaths and all-cause deaths through numerous Peruvian national health databases, allowing researchers to calculate excess deaths. Additionally, they extensively tracked data for deaths and other public health parameters allowing analysis of the potential efficacy of interventions such as ivermectin during the pandemic.
When President Francisco Sagasti took office on Nov. 17, 2020, the government stopped distributing ivermectin and made it available only by prescription. This made the drug significantly more difficult for people to obtain and allowed researchers to see nationwide changes in daily excess all-cause deaths before and after restrictions went into place.
Impact of Ivermectin on Excess Deaths
Excess all-cause deaths were calculated from the total deaths recorded for January through February 2020. During this period, monthly all-cause deaths fluctuated with a mean value of 5.2 percent and a standard deviation of 3.8 percent. By May 2020, total deaths fluctuated by more than double the baseline value calculated in January through February.
An analysis of excess all-cause deaths was performed state-by-state for those aged 60 years and older to establish the date of peak excess deaths during the pandemic’s first wave. Decreases in excess deaths from the peak date of death to 30 and 45 days afterward were tracked. The 25 states were then grouped by the extent of ivermectin distribution: maximal distribution—occurring through operation MOT, medium, and minimal.
Results showed that the 10 MOT states had a sharp decrease in excess deaths after reaching peak values—with a 74 percent drop at 30 days and an 86 percent drop at 45 days after the date of peak deaths. For 14 states that locally administered ivermectin, excess deaths dropped by 53 percent at 30 days and 70 percent at 45 days.
In Lima, where ivermectin treatments were delayed until August—four months after its initial pandemic surge in April—excess deaths only dropped by 25 percent at 30 days and 25 percent at 45 days after peak deaths on May 30.
According to the study, mean reductions in excess deaths 30 days after peak deaths were 74 percent, 53 percent, and 25 percent, respectively, for the maximal, medium, and minimal states that distributed ivermectin. Forty-five days after peak deaths, mean reductions were 86 percent, 70 percent, and 25 percent.
The researchers noted that ivermectin distribution may have yielded such positive numbers due to the drug’s ability to both prevent and treat COVID-19 when distributed to an at-risk population on a greater scale.
Read more here...

 

[Valcazar]

What have they added from the last time they published this study?

 

[Addict2sex]

What have they added from the last time they published this study?

Why don’t you read this peer reviewed study yourself… I guessing you are highly knowledgeable in the medical field. Mostly a med student or premed student ( maybe a second year resident). The link is at the source ..you afraid find out the truth? That you been lied
all along! Go check it out yourself! If you have any integrity and believe the hyporocratic oath ( When you graduate first do no harm)!
At least you will win my respect if you man up and admit you were wrong and fell for the lies from mainstream media and the blue team, Then you will at least win my respect and save face when you look yourself in the mirror!

 

[basketcase]

Still pushing Big Pharma's drugs?

 

[squeezer]

ADDICT, how did I miss this gem of the comical thread you started?? Keep it up man, you will make it big one day, guaranteed!!!

 

[Valcazar]

Why don’t you read this peer reviewed study yourself… I guessing you are highly knowledgeable in the medical field. Mostly a med student or premed student ( maybe a second year resident). The link is at the source ..you afraid find out the truth? That you been lied
all along! Go check it out yourself! If you have any integrity and believe the hyporocratic oath ( When you graduate first do no harm)!
At least you will win my respect if you man up and admit you were wrong and fell for the lies from mainstream media and the blue team, Then you will at least win my respect and save face when you look yourself in the mirror!

I'd have to read this study and then closely compare it to the one they published in 2021 and see if they have any new data of note in it.
(At first glance it doesn't seem so.)

The Peru data has been discussed for over two years now.
If you are hyping it up again, I'd like to know what new element there is to focus on.